Related Experiment Video
Updated: May 12, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Assessment of the Prognostic Value of Monocyte-to-HDL Ratio in ST-Elevation Myocardial Infarction Patients Undergoing
Ahmad Separham1, Naser Aslan-Abadi1, Hamid Sedigh1
1Cardiovascular Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Insights
The monocyte-to-high-density lipoprotein ratio (MHR) is a significant predictor of adverse outcomes in ST-segment elevation myocardial infarction (STEMI) patients. Higher MHR levels are independently associated with increased in-hospital mortality and major adverse cardiovascular events (MACE) after primary percutaneous coronary intervention (PCI).
Area of Science:
- Cardiology
- Inflammation Markers
- Clinical Prognostics
Background:
- Inflammation plays a crucial role in ST-segment elevation myocardial infarction (STEMI).
- The monocyte-to-high-density lipoprotein ratio (MHR) is an emerging inflammatory marker.
- Assessing MHR's prognostic value in STEMI patients undergoing primary percutaneous coronary intervention (PCI) is important.
Purpose of the Study:
- To evaluate the prognostic significance of the monocyte-to-high-density lipoprotein ratio (MHR).
- To determine MHR's association with inflammation in STEMI patients undergoing primary PCI.
Main Methods:
- Retrospective cross-sectional study of 652 STEMI patients who underwent primary PCI.
- Patients were stratified based on admission MHR median.
- Clinical, demographic, and laboratory data were analyzed from medical records.
Main Results:
- Higher MHR levels were correlated with increased in-hospital mortality and major adverse cardiovascular events (MACE).
- MHR demonstrated predictive capability for in-hospital mortality (75.7% sensitivity, 53.5% specificity) and MACE (60.2% sensitivity, 59.7% specificity).
- Multivariate analysis confirmed MHR as an independent predictor of in-hospital mortality and MACE.
Conclusions:
- Elevated MHR is independently linked to a greater risk of MACE.
- Increased MHR is associated with higher in-hospital mortality in STEMI patients post-primary PCI.
Background:
The purpose of this study was to assess the prognostic value of the monocyte-to-high-density lipoprotein ratio (MHR) as a marker of inflammation in patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).
Materials And Methods:
This retrospective cross-sectional study was conducted on patients with a diagnosis of STEMI who underwent PCI between March 2021 and March 2022 at Madani Training and Research Hospital in Tabriz, Iran. Data regarding clinical and demographic properties, and laboratory parameters were obtained from medical records. Patients were categorized into two groups according to the median of admission MHR.
Results:
The study population consisted of 652 patients, 378 males (58%), and 275 females (42%), with a median age of 68 years (interquartile range: 57-77). Results showed that groups with higher MHR (15.59) had higher rates of in-hospital mortality and higher major adverse cardiovascular events (MACEs) in comparison with the group featuring lower MHR (15.59). Receiver operating characteristic (ROC) curves demonstrated that MHR could predict in-hospital mortality with a 75.7% sensitivity and 53.5% specificity, as well as predict MACE with 60.2% sensitivity and 59.7% specificity. Multivariate analyses indicated that MHR is an independent predictor of both in-hospital mortality (OR 1.05, 95% CI 1.02-1.08, P=0.002) and MACE (OR 1.05, 95% CI 1.02-1.08, P0.001).
Conclusion:
This research indicated that the rise in MHR was independently associated with a higher risk of MACE and in-hospital mortality in STEMI patients undergoing primary PCI.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies